ReviewCureus2026
GLP-1 Receptor Agonists in the Management of Post-bariatric Weight Regain and Dysglycemia: A Systematic Review and Meta-Analysis.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Weight regain, insufficient weight loss, and metabolic relapse (including dysglycemia) are increasingly recognized long-term challenges following bariatric surgery. Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) have been explored as a potential adjunctive therapy in this setting, though evidence on their effects in post-bariatric populations remains limited and variable. This systematic review and meta-analysis was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. A comprehensive search of electronic databases identified studies evaluating GLP-1 RA therapy in adults following bariatric surgery for weight regain, insufficient weight loss, or persistent/recurrent dysglycemia. Thirteen studies met the inclusion criteria and were included in the quantitative meta-analysis of weight outcomes. A random-effects model was used to pool mean weight change, with heterogeneity assessed via the I² statistic. Publication bias was evaluated using funnel plots and Egger's regression test. Across the 13 studies, GLP-1 RA therapy was associated with a pooled mean weight reduction of 7.45 kg (95% CI -8.78 to -6.11). However, substantial heterogeneity was present (I² = 89.8%), likely attributable to differences in study designs, patient characteristics, bariatric procedures, GLP-1 RA agents/doses, and follow-up durations. Funnel plot inspection and Egger's test (p = 0.29) did not indicate significant publication bias or small-study effects. While these findings suggest that GLP-1 RAs may offer a non-invasive adjunctive option for managing post-bariatric weight regain and inadequate weight loss, the high heterogeneity and predominance of observational studies limit the strength of conclusions. GLP-1 RAs appear promising in addressing appetite dysregulation and metabolic signaling in this population, but further high-quality, randomized controlled trials with longer follow-up are needed to confirm efficacy, optimize treatment regimens, and better evaluate glycemic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.